Figure F-119 is titled “Change in SDS for SSRIs compared with placebo: Sensitivity analysis including studies with high risk of bias.” The figure displays a forest plot reporting the weighted mean difference in SDS stratified by fluoxetine compared with placebo, paroxetine compared with placebo, and sertraline compared with placebo. The plot depicts greater reductions in SDS scores for patients treated with fluoxetine (2 trials, weighted mean difference −2.32, 95% CI −9.92 to 5.28), paroxetine (3 trials, weighted mean difference −2.32, 95% CI −3.28 to −1.36, I2=0.0%), and sertraline (1 trial, weighted mean difference −1.65, 95% CI −3.42 to 0.12) than placebo. The overall analysis continued to favor SSRIs over placebo (weighted mean difference −2.26, 95% CI −3.15 to −1.38, I2=10.05%) with the inclusion of high risk of bias of studies.

Figure F-119Change in SDS for SSRIs compared with placebo: Sensitivity analysis including studies with high risk of bias

Note: Hertzberg et al., 2000 was rated as high risk of bias.

Timing of outcome assessment: 12 weeks for all included studies.

From: Appendix F, Meta-Analysis

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.